BiotechTube
DiaMonTech

DiaMonTech

Berlin, Germany· Est.
diamontech.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

DiaMonTech is a private, pre-revenue diagnostics company pioneering non-invasive glucose monitoring using a proprietary mid-infrared laser technology. Its core development programs are the D-Pocket handheld monitor and the D-Sensor, a miniaturized module being co-developed with Samsung for integration into smartwatches. The company aims to disrupt the multi-billion-dollar glucose monitoring market by eliminating the need for finger-prick blood sampling, offering a solution for both diabetic management and general wellness tracking. Backed by an experienced team and strategic partnerships, DiaMonTech is navigating the rigorous regulatory pathway required for medical device approval.

Diabetes

Technology Platform

Patented mid-infrared laser spectroscopy using Infrared Excitation – Photothermal Deflection (IRE-PTD) to non-invasively detect and measure glucose molecules in interstitial fluid.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The global diabetes epidemic creates a massive, growing market for pain-free monitoring solutions.
Successful miniaturization into wearables (via the Samsung partnership) could open the even larger preventative health and wellness market.
Non-invasive technology offers a compelling value proposition to replace both finger-stick meters and invasive CGMs.

Risk Factors

The primary risk is the formidable technical and clinical challenge of achieving regulatory-grade accuracy with a non-invasive method across all user conditions.
The path to market is long, expensive, and uncertain, requiring significant capital.
The company faces intense competition from well-funded incumbents with established products and loyalty.

Competitive Landscape

DiaMonTech competes in the glucose monitoring space dominated by Abbott (FreeStyle Libre), Dexcom, and Medtronic, which offer minimally invasive CGM systems. It also faces potential competition from other companies developing non-invasive technologies (e.g., using optical sensors). Its key differentiator is the high-selectivity mid-IR laser approach, but it must prove clinical superiority or parity to gain market share.

More companies in Diagnostics & Precision Medicine →More companies in Germany →